Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | DCTPP1 | Q9H773 | 1/20 | 0.31 |
| ▸ | TNKS | O95271 | 1/20 | 0.30 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5265367 | 0.83 | POLB (0.33) | POLBLMNATP53DCTPP1TNKS | |
| SCHEMBL5262872 | 0.80 | TNKS (0.35) | POLBLMNATP53TNKSTNKS2 | |
| SCHEMBL5263885 | 0.76 | DCTPP1 (0.36) | POLBLMNADCTPP1TNKSTNKS2 | |
| SCHEMBL5266123 | 0.75 | MEN1 (0.50) | LMNA | |
| SCHEMBL5262020 | 0.75 | LMNA (0.39) | POLBLMNA | |
| SCHEMBL5266152 | 0.74 | ALDH1A1 (0.37) | POLBTP53 | |
| SCHEMBL5261625 | 0.74 | DCTPP1 (0.35) | POLBLMNADCTPP1TNKSTNKS2 | |
| SCHEMBL5262413 | 0.74 | POLB (0.33) | POLBLMNATP53DCTPP1 | |
| SCHEMBL5261108 | 0.74 | CYP19A1 (0.39) | POLBLMNA | |
| SCHEMBL5262954 | 0.74 | SUV39H2 (0.38) | LMNATP53DCTPP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050124607-A1 | 5-Substituted quinazolinone compounds useful as alpha 1A/B adrenergic receptor antagonists | ROCHE PALO ALTO LLC | 2005-06-09 | — | — | US | claimed |
| EP-1644343-B1 | 5-SUBSTITUTED QUINAZOLINONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2007-07-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124607-A1 | 5-Substituted quinazolinone compounds useful as alpha 1A/B adrenergic receptor antagonists | ADRB1, ADRA1B, ADRB2 | POLB 1321/4885LMNA 2114/4885TP53 3934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.